Cagrilintide is developed by Novo Nordisk, the same company behind semaglutide (Ozempic/Wegovy) and the CagriSema combination
In general, tryptophan metabolism is also impaired in IBD
To view a copy of this licence, visit About this article Cite this article Schreier, P.C.F., Beyerle, P., Boulassel, S
Prem S, Dev B, Peng C, Mehta M, Alibutud R, Connacher RJ, St Thomas M, Zhou X, Matteson P, Xing J, Millonig JH, DiCicco-Bloom E (2024) Dysregulation of mTOR signaling mediates common neurite and migration defects in both idiopathic and 16p11.2 deletion autism neural precursor cells
Summary: There is currently no established causal link between Ozempic (semaglutide) and hearing loss according to MHRA, EMA, or official product literature